These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 14730168

  • 1. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
    Aksoy Y, Aksoy H, Bakan E, Atmaca AF, Akçay F.
    Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168
    [Abstract] [Full Text] [Related]

  • 2. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [Abstract] [Full Text] [Related]

  • 3. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [Abstract] [Full Text] [Related]

  • 4. [Analysis of serum insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 in benign prostatic hyperplasia].
    Yu JP, Wu XM, Chen JG, Liu WM, Yang QX.
    Zhonghua Nan Ke Xue; 2003 Aug; 9(5):341-3. PubMed ID: 14513639
    [Abstract] [Full Text] [Related]

  • 5. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
    Miyata Y, Sakai H, Hayashi T, Kanetake H.
    Prostate; 2003 Feb 01; 54(2):125-32. PubMed ID: 12497585
    [Abstract] [Full Text] [Related]

  • 6. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
    Khosravi J, Diamandi A, Mistry J, Scorilas A.
    J Clin Endocrinol Metab; 2001 Feb 01; 86(2):694-9. PubMed ID: 11158033
    [Abstract] [Full Text] [Related]

  • 7. Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3.
    Safarinejad MR, Shafiei N, Safarinejad S.
    Growth Horm IGF Res; 2011 Jun 01; 21(3):146-54. PubMed ID: 21536469
    [Abstract] [Full Text] [Related]

  • 8. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men.
    Kehinde EO, Akanji AO, Mojiminiyi OA, Bashir AA, Daar AS, Varghese R.
    Prostate Cancer Prostatic Dis; 2005 Jun 01; 8(1):84-90. PubMed ID: 15775992
    [Abstract] [Full Text] [Related]

  • 9. [Vascular endothelial growth factor and insulin-like-growth factors in prostate cancer. ].
    Trapeznikova MF, Shibaeva AN, Ianshin AA, Urenkov SB, Mironova OS, Kazantseva IA, Kushlinskiĭ NE.
    Urologiia; 2004 Jun 01; (1):17-21. PubMed ID: 15022438
    [Abstract] [Full Text] [Related]

  • 10. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE, Holly J, Peters TJ, Donovan J, Persad R, Gillatt D, Pearce A, Hamdy FC, Neal DE, Gunnell D.
    Urology; 2004 Aug 01; 64(2):317-22. PubMed ID: 15302487
    [Abstract] [Full Text] [Related]

  • 11. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
    Hong SK, Han BK, Jeong JS, Jeong SJ, Moon KH, Byun SS, Lee SE.
    Asian J Androl; 2008 Mar 01; 10(2):207-13. PubMed ID: 18097534
    [Abstract] [Full Text] [Related]

  • 12. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.
    Eur Urol; 2006 Feb 01; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [Abstract] [Full Text] [Related]

  • 13. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and prostate cancer: correlation with Gleason score.
    Correa LL, Neto LV, Lima GA, Gabrich R, Miranda LC, Gadelha MR.
    Int Braz J Urol; 2015 Feb 01; 41(1):110-5. PubMed ID: 25928516
    [Abstract] [Full Text] [Related]

  • 14. Insulin-like growth factors and risk of benign prostatic hyperplasia.
    Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Sesterhenn IA, Mostofi FK, Fraumeni JF, Hsing AW.
    Prostate; 2002 Jul 01; 52(2):98-105. PubMed ID: 12111701
    [Abstract] [Full Text] [Related]

  • 15. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
    Sciarra A, Gentile V, Monti S, Dattilo C, Autran Gomez A, Salciccia S, Pannunzi LP, Toscano V, Di Silverio F.
    Urol Int; 2008 Jul 01; 80(1):68-73. PubMed ID: 18204237
    [Abstract] [Full Text] [Related]

  • 16. Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
    Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF, Hsing AW.
    Cancer Epidemiol Biomarkers Prev; 2001 May 01; 10(5):421-7. PubMed ID: 11352850
    [Abstract] [Full Text] [Related]

  • 17. Analysis of insulin like growth factor 1 and insulin like growth factor binding protein 3 levels in bronchoalveolar lavage fluid and serum of patients with lung cancer.
    Unsal E, Köksal D, Yurdakul AS, Atikcan S, Cinaz P.
    Respir Med; 2005 May 01; 99(5):559-65. PubMed ID: 15823452
    [Abstract] [Full Text] [Related]

  • 18. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
    Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D.
    Cancer Res; 2003 Jul 15; 63(14):3991-4. PubMed ID: 12873996
    [Abstract] [Full Text] [Related]

  • 19. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.
    Nam RK, Trachtenberg J, Jewett MA, Toi A, Evans A, Emami M, Narod SA, Pollak M.
    Cancer Epidemiol Biomarkers Prev; 2005 May 15; 14(5):1270-3. PubMed ID: 15894684
    [Abstract] [Full Text] [Related]

  • 20. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
    Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ.
    Urol Oncol; 2012 May 15; 30(4):408-14. PubMed ID: 20884247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.